GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
J

Jiangsu Yahong Meditech Co 688176.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

11.18

-1.41%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Jiangsu Yahong Meditech Co

Its shares trade on Shanghai under the ticker 688176.SS. It has been listed since 7 January 2022. In the fiscal year to 31 December 2025, it reported revenue of CN¥277.1m and a net loss of CN¥419.3m. At that date it held total assets of CN¥2.06bn and shareholders' equity of CN¥1.58bn.

Jiangsu Yahong Meditech Co., Ltd. engages in the research, development, production and commercialization of medicines in the fields of urogenital system tumors and other major diseases fields. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2022-01-07. The firm focuses on innovative drugs in the field of urogenital tumors and other major diseases. The product pipelines being developed by the Company include APL-1202, APL-1501, APL-1706, APL-1702, ASN-1764, ASN-1780, APL-1901, APL-1401, ASN-1733 and others. The firm is still in the R&D stage.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
7 Jan 2022
Employees
231

Leadership

Pay as last reported

  • Dr. Ke PanChairman of the Board, General Manager, since 2020
  • Mr. Mingyuan YangFinance Director, Acting Secretary of the Board, Director, since 2020
  • Ms. Susan WangSenior Vice President - Global Business Development
  • Mr. Tielin WangSenior Vice President - Head of Discovery Chemistry and Pre-Clinical Development
  • Mr. Yijun DengVice President, Director, since 2020
  • Dr. Chengfeng ZhuangDeputy General Manager, Director, since 2019
  • Mr. Yong XueChief Medical Officer
  • Mr. Wende ChenDirector
  • Mr. Xinming JiangDirector
  • Mr. Xianxian LiDirector
  • Mr. Bin HuangIndependent Director
  • Ms. Wenning WangIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Innovative drug pipeline includes APL-1202 and APL-1501 for urogenital tumors
  • 231 full-time employees support R&D in pharmaceuticals
  • IPO on 7 January 2022 provides capital for growth

Weaknesses

  • R&D stage limits immediate revenue generation
  • No commercialized products yet in urogenital tumor field
  • Company remains in early development phase

Opportunities

  • Growing demand for urogenital tumor treatments in China
  • Expansion into other major disease fields like ASN-1764
  • Potential partnerships with healthcare providers in Shanghai

Threats

  • Competition from established pharmaceutical firms in CN
  • Regulatory challenges in Chinese pharmaceutical market
  • Market volatility affecting R&D funding in Health Care sector

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.